More case studies
Challange
A leading global biopharmaceutical company urgently required 10,000 doses of the Fluarix QIV Southern Hemisphere Vaccine 2025, after being unexpectedly let down by their original supplier in Brazil. The situation was complicated by the vaccine’s discontinuation in many markets, severely limiting global availability. The timing was critical as vaccine stock was rapidly becoming unavailable due to pre-booking commitments.
Solution
CSI swiftly responded by quickly onboarding the client and immediately initiating efforts to secure the necessary vaccine supply. Within one week, CSI successfully identified and secured a suitable batch of the Southern Hemisphere strain vaccine. Acting decisively, CSI pre-booked the vaccine within days, preventing the allocation of doses to other buyers, and ensured timely delivery to Singapore.
Result
CSI’s rapid action and expert sourcing capability resulted in successful initial delivery, meeting the client’s urgent need. When additional demand arose post-delivery, CSI leveraged its market expertise and strong relationships with local marketing authorization holders to secure an extra 2,000 doses despite closed pre-booking periods. This proactive and efficient approach greatly satisfied the client, leading to further engagements with CSI for continued sourcing support.
Case Study
Rapid Sourcing of Discontinued Southern Hemisphere Vaccine for a Global Biopharmaceutical Client
A leading global biopharmaceutical company urgently requested CSI to supply the Fluarix QIV Southern Hemisphere Vaccine for 2025.
Challange
A global biopharmaceutical company urgently needed 10,000 doses of the Fluarix QIV Southern Hemisphere Vaccine 2025 due to a sudden supplier failure in Brazil, amid limited global availability and rapidly closing pre-booking windows.
Solution
CSI acted quickly, securing the required vaccine batch within one week and promptly pre-booking to ensure timely delivery to Singapore.
Result
CSI’s efficient response led to successful initial delivery and additional sourcing of 2,000 extra doses, significantly satisfying the client and leading to further collaboration.
Contact us
Get in touch with a member of our experienced team today to discuss your clinical trial supply requirements
.png){kind=logo}